Pharmacogenetics testing for poor response to antidepressants: a transnosographic case series
IntroductionPharmacogenetics (PGx) holds promise for optimizing psychotropic medication use, with CYP2D6 and CYP2C19 identified as key genes in antidepressant treatment. However, few studies have explored the genetic variants of these genes in real-world settings for patients experiencing ineffectiv...
Saved in:
Main Authors: | Marie-Agnès Lorvellec (Author), Gilles Sipahimalani (Author), Bertrand Lahutte (Author), Hervé Delacour (Author), Antoine Baldacci (Author), Emeric Saguin (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenetic Guidelines for Psychotropic Drugs: Optimizing Prescriptions in Clinical Practice
by: Antoine Baldacci, et al.
Published: (2023) -
Pharmacogenetics of antidepressants
by: Concetta eCrisafulli, et al.
Published: (2011) -
Pharmacogenetics of antidepressant drugs: An update
by: Crisafulli Concetta, et al.
Published: (2014) -
Comparing commercial pharmacogenetic testing results and recommendations for antidepressants with established CPIC guidelines
by: Tiffany T. Nguyen, et al.
Published: (2024) -
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy
by: Sony Tuteja, et al.
Published: (2022)